Brochure: Get to Market Faster with the Opto CLD Workflow
Find out how the Opto CLD workflow sets a new standard for quality, capacity, and speed in cell line development to let BioPharma get more molecules to the clinic faster.
Download FileRelated Resources
View All ResourcesBROCHURE: Beacon Select™ Optofluidic System for CLD | A4
- Approximately half the price of the 4-chip Beacon system
- A 2-chip automated optofluidic system, similar to the 4-chip Beacon® optofluidic system, which provides well-established workflows that have been adopted by ~130 customers
- Throughput scaled to meet the needs of small to mid-sized biopharma and CDMO/CRO companies
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
APP NOTE: Identify Top Producing Clones with Favorable Product Quality Attributes | A4
- Identify clones with favorable growth, titer, and product quality attributes prior to scale up
- Go from transfected pools to top clones in under one week for a wide variety of protein therapeutics, including protein-based vaccines,
enzymes and bispecific molecules - Cloning efficiencies 5x greater than FACS and 10x greater than limiting dilution, and >99% monoclonality assurance